Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BVS NASDAQ:CLPT NASDAQ:PROF NASDAQ:SIBN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$7.02+4.6%$7.01$5.81▼$14.38$580.41M0.81390,365 shs248,263 shsCLPTClearPoint Neuro$27.38+9.3%$12.63$9.76▼$28.80$778.33M1.191.36 million shs2.50 million shsPROFProfound Medical$5.68+7.0%$4.83$3.76▼$9.17$170.94M0.66151,336 shs58,589 shsSIBNSiBone$14.50+1.3%$15.76$11.70▼$20.05$625.54M0.83418,850 shs346,324 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus0.00%+5.41%-1.13%-1.74%-40.41%CLPTClearPoint Neuro0.00%+27.05%+147.11%+131.05%+150.96%PROFProfound Medical0.00%+8.81%+28.51%-5.10%-30.39%SIBNSiBone0.00%+3.20%-11.31%-21.45%+6.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$7.02+4.6%$7.01$5.81▼$14.38$580.41M0.81390,365 shs248,263 shsCLPTClearPoint Neuro$27.38+9.3%$12.63$9.76▼$28.80$778.33M1.191.36 million shs2.50 million shsPROFProfound Medical$5.68+7.0%$4.83$3.76▼$9.17$170.94M0.66151,336 shs58,589 shsSIBNSiBone$14.50+1.3%$15.76$11.70▼$20.05$625.54M0.83418,850 shs346,324 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus0.00%+5.41%-1.13%-1.74%-40.41%CLPTClearPoint Neuro0.00%+27.05%+147.11%+131.05%+150.96%PROFProfound Medical0.00%+8.81%+28.51%-5.10%-30.39%SIBNSiBone0.00%+3.20%-11.31%-21.45%+6.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBVSBioventus 2.75Moderate Buy$13.7595.87% UpsideCLPTClearPoint Neuro 2.50Moderate Buy$19.67-28.17% DownsidePROFProfound Medical 2.00Hold$11.0093.66% UpsideSIBNSiBone 2.50Moderate Buy$23.6763.22% UpsideCurrent Analyst Ratings BreakdownLatest PROF, CLPT, SIBN, and BVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025CLPTClearPoint NeuroWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025PROFProfound MedicalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025SIBNSiBoneWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)8/11/2025SIBNSiBoneCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$25.008/5/2025SIBNSiBoneCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$25.008/1/2025CLPTClearPoint NeuroStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $9.007/7/2025BVSBioventusCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$12.00(Data available from 10/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBVSBioventus$564.14M1.03$0.56 per share12.58$2.80 per share2.51CLPTClearPoint Neuro$31.39M24.80N/AN/A$0.92 per share29.76PROFProfound Medical$10.68M16.02N/AN/A$2.01 per share2.83SIBNSiBone$167.18M3.74N/AN/A$3.98 per share3.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBVSBioventus-$156.23MN/AN/A15.26N/A-7.11%15.61%4.01%N/ACLPTClearPoint Neuro-$18.91M-$0.81N/AN/AN/A-66.15%-94.44%-51.58%11/6/2025 (Estimated)PROFProfound Medical-$27.82M-$1.46N/AN/AN/A-343.97%-89.74%-73.06%11/6/2025 (Estimated)SIBNSiBone-$30.91M-$0.56N/AN/AN/A-12.83%-14.20%-10.38%11/11/2025 (Estimated)Latest PROF, CLPT, SIBN, and BVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PROFProfound Medical-$0.43-$0.52-$0.09-$0.52$4.75 million$2.21 million8/12/2025Q2 2025CLPTClearPoint Neuro-$0.20-$0.21-$0.01-$0.21$9.20 million$9.22 million8/4/2025Q2 2025SIBNSiBone-$0.19-$0.14+$0.05-$0.14$48.12 million$48.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBVSBioventusN/AN/AN/AN/AN/ACLPTClearPoint NeuroN/AN/AN/AN/AN/APROFProfound MedicalN/AN/AN/AN/AN/ASIBNSiBoneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBVSBioventus1.851.410.99CLPTClearPoint Neuro1.467.306.45PROFProfound Medical0.118.537.07SIBNSiBone0.218.387.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBVSBioventus62.94%CLPTClearPoint Neuro30.08%PROFProfound Medical47.86%SIBNSiBone98.11%Insider OwnershipCompanyInsider OwnershipBVSBioventus33.00%CLPTClearPoint Neuro6.97%PROFProfound Medical1.52%SIBNSiBone4.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBVSBioventus1,20082.68 million54.46 millionNot OptionableCLPTClearPoint Neuro11028.43 million26.45 millionOptionablePROFProfound Medical15030.12 million29.66 millionOptionableSIBNSiBone35043.14 million41.42 millionOptionablePROF, CLPT, SIBN, and BVS HeadlinesRecent News About These CompaniesDATA BREACH ALERT: Edelson Lechtzin LLP is Investigating Claims on Behalf of SI-Bone, Inc. Customers Whose Data May Have Been CompromisedOctober 3 at 12:20 PM | globenewswire.comSiBone (NASDAQ:SIBN) Stock Price Down 4.2% - Here's WhyOctober 1, 2025 | marketbeat.comSiBone (NASDAQ:SIBN) versus RxSight (NASDAQ:RXST) Critical ReviewOctober 1, 2025 | americanbankingnews.comPalumbo Wealth Management LLC Buys Shares of 30,649 SiBone $SIBNSeptember 25, 2025 | marketbeat.comHarbor Capital Advisors Inc. Raises Stake in SiBone $SIBNSeptember 17, 2025 | marketbeat.comSiBone $SIBN Shares Bought by Goldman Sachs Group Inc.September 17, 2025 | marketbeat.comSI-BONE, Inc. (SIBN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 9, 2025 | seekingalpha.comTrexquant Investment LP Has $1.62 Million Holdings in SiBone $SIBNSeptember 8, 2025 | marketbeat.comGranahan Investment Management LLC Decreases Holdings in SiBone $SIBNSeptember 7, 2025 | marketbeat.comSI-BONE to Present at Morgan Stanley 23rd Global Healthcare Conference on September 9, 2025August 26, 2025 | globenewswire.comSiBone (NASDAQ:SIBN) SVP Sells $52,065.56 in StockAugust 21, 2025 | insidertrades.comInsider Selling: SiBone (NASDAQ:SIBN) Director Sells 12,132 Shares of StockAugust 12, 2025 | insidertrades.comSI-Bone Reports Strong Q2 2025 Financial ResultsAugust 5, 2025 | msn.comSI-BONE, Inc. (SIBN) Q2 2025 Earnings Call TranscriptAugust 5, 2025 | seekingalpha.comSI-BONE, Inc. 2025 Q2 - Results - Earnings Call PresentationAugust 4, 2025 | seekingalpha.comSi-Bone (SIBN) Reports Q2 Loss, Beats Revenue EstimatesAugust 4, 2025 | zacks.comSI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 and Raises 2025 GuidanceAugust 4, 2025 | globenewswire.comSI-BONE To Present at Canaccord Genuity 45th Annual Growth Conference on August 12, 2025July 29, 2025 | globenewswire.comSI-BONE To Report Second Quarter 2025 Financial Results on August 4, 2025July 14, 2025 | globenewswire.comInsider Selling: SiBone (NASDAQ:SIBN) CEO Sells 757 Shares of StockJuly 8, 2025 | insidertrades.comAll You Need to Know About Si-Bone (SIBN) Rating Upgrade to BuyJuly 7, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhy Opendoor Stock Is Soaring—and May Just Be StartingBy Jeffrey Neal Johnson | September 16, 2025After a Strong Wall Street Debut, Klarna's Real Work BeginsBy Jeffrey Neal Johnson | September 15, 2025Alphabet: Time to Take Profits, Buy, or Wait for a Pullback?By Ryan Hasson | September 25, 2025How Bath & Body Works Is a Perfect Example of a Value Stock By Gabriel Osorio-Mazilli | September 16, 2025Beam Global Gets Buy Rating With 101% Upside PotentialBy Nathan Reiff | September 27, 2025PROF, CLPT, SIBN, and BVS Company DescriptionsBioventus NYSE:BVS$7.02 +0.31 (+4.62%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$7.03 +0.01 (+0.09%) As of 10/3/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.ClearPoint Neuro NASDAQ:CLPT$27.38 +2.33 (+9.30%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$27.79 +0.41 (+1.49%) As of 10/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.Profound Medical NASDAQ:PROF$5.68 +0.37 (+6.97%) Closing price 10/3/2025 03:59 PM EasternExtended Trading$5.68 0.00 (-0.09%) As of 10/3/2025 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.SiBone NASDAQ:SIBN$14.50 +0.19 (+1.33%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$14.50 0.00 (0.00%) As of 10/3/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength How Berkshire's OxyChem Buy Cements Its Long-Term Strength The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
